Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A multicenter randomized phase III study to compare capecitabine alone or in combination with trastuzumab in patients with HER2 positive metastatic breast cancer and progression after previous treatment with trastuzumab.

Next Previous
Trial Profile

A multicenter randomized phase III study to compare capecitabine alone or in combination with trastuzumab in patients with HER2 positive metastatic breast cancer and progression after previous treatment with trastuzumab.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 19 Dec 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Trastuzumab (Primary) ; Capecitabine
  • Indications Advanced breast cancer; HER2 negative breast cancer; HER2 positive breast cancer
  • Focus Therapeutic Use
  • Acronyms TBP

    • Most Recent Events

    • 22 Feb 2011 Actual end date (Jan 2011) added as reported by ClinicalTrials.gov.
    • 05 May 2010 Results of a cost-utility analysis based on this trial have been published in the Annals of Oncology.
    • 07 Apr 2009 New source identified and integrated (United Kingdom Clinical Research Network 1087413)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top